Drugs / BNT317
last change Jan 2025 re-read 3 minutes ago

BNT317

Developed for
neoplasm
Investigated by
BioNTech SE

Trials 1

2025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT06750185 Jan 2025 → Jun 2028 expected neoplasm BioNTech SE Recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as BNT317 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06750185 ↗
Route Intravenous “Intravenous infusion” NCT06750185 ↗